{
  "id": 12241482,
  "title": "Why is Vaxcyte stock sliding in after-hours trading today?",
  "url": "https://urgent.news/2026/10/05/why-is-vaxcyte-stock-sliding-in-after-hours-trading-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-05T21:43:59.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-vaxcyte-stock-sliding-in-afterhours-trading-today-93CH-4932984"
  },
  "original_language": "en",
  "account": "Vaxcyte Inc. shares experienced a steep 5.8% drop in after-hours trading following the announcement of a $1 billion dual capital raise. The offering encompasses $500 million in common stock and pre-funded warrants, coupled with $500 million in convertible senior notes due in 2032. Underwriters retain the option to purchase $75 million in each tranche for a 30-day period, increasing the possibility of substantial share dilution. This news follows Vaxcyte's announcement that its 31-valent pneumococcal conjugate vaccine candidate, VAX-31, achieved all prespecified co-primary immunogenicity endpoints in the pivotal adult OPUS-1 Phase 3 trial. The trial involved over 4,000 participants across 30 U.S. sites, with all 28 serotypes shared with competitors meeting noninferiority criteria, and several unique VAX-31 serotypes demonstrating superiority. Analysts praised the outcome, with Jefferies' Roger Song describing it as a \"blue-sky\" scenario and BTIG calling it a \"clean sweep\" of all 32 co-primary endpoints, maintaining a Buy rating with an $89 price target. Despite the positive intraday rally, the broader market remained unchanged, with the S&P 500, Dow Jones, and NASDAQ all finishing essentially flat. The after-hours decline highlights the biotech industry's tendency to sell shares following well-received data, as companies use the elevated share price to fund future development and manufacturing scale-up.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}